January 30, 2012—The Centers for Medicare and Medicaid Services (CMS) has published its long-awaited proposed rule to implement the Medicaid average manufacturer price (AMP) and best price (BP) provisions of the Affordable Care Act (ACA).
Once finalized, the rule will have major implications for prices paid for 340B-discounted drugs. CMS is accepting comments on its proposal through April 2.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)